Hem

Press release from Companies

Publicerat: 2021-12-09 13:54:22

Eevia Health Plc: Resolutions of Eevia Health Plc’s Extraordinary General Meeting on December 9, 2021

An Extraordinary General Meeting ("EGM") of shareholders of Eevia Health Plc was held in Seinäjoki, on December 9, 2021. Three shareholders representing 2,882,200 shares and votes (20,6 % of total shares) were represented at the meeting. The EGM unanimously decided on the proposal from the Board of Directors as described in the Notice of Extraordinary General Meeting.

The Extraordinary General Meeting resolved on the following issue:

Authorizing the Board of Directors to decide on issuance of shares

The EGM resolved in accordance with the proposal from the Board of Directors to authorize the Board of Directors to decide, in one or more transactions, on the issuance of shares against payment as follows: The number of shares to be issued based on the authorization may in total amount to a maximum of 2,061,856 shares. The Board of Directors decides on all other terms and conditions of the issuances of shares. The issuance of shares may be carried out in deviation from the shareholders’ pre-emptive rights (directed issue), if there is a weighty financial reason for the company. The authorization is valid until May 31st, 2022.

Resolution on directed share issue by the Board of Directors

The Board of Directors of Eevia Health Plc has resolved, based on the authorization received from the Extraordinary General Meeting, on a directed new issue of 2,061,856 shares at a subscription price of SEK 9.70 per share (the "Directed Share Issue"), which is expected to raise proceeds to the Company of SEK 20 million before issue costs. The purpose of the Directed Share Issue is to increase and broaden the shareholder base with qualified and long-term investors and also in a cost-effective and timely manner raise capital to improve the Company's financial position and to enable the further development and growth of the Company's business. The Board is of the opinion that the Directed Share Issue will be of benefit to the Company and, therefore, to all its shareholders.

Other information related to the Directed Share Issue has been published on 11 November 2021 in a press release.

For more information, please contact: 

Kim Nurmi-Aro, CFO

kim@eeviahealth.com

Tel.: +358 504 44 0717

About Eevia

Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild-harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.

Eevia Health is a fast-growing Finnish manufacturer of 100% organically certified plant extracts. Although a significant product; Elderberry extract, is made from cultivated berries, most of Eevia’s other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion. Eevia’s branded ingredients, such as Feno-Myrtillus® Organic (high concentrate bilberry extracts with 36% anthocyanins) and Fenoprolic® 70 Organic (pine bark extracts with 70% oligomeric proanthocyanidins), are organically certified. 

Eevia Health operates a modern green-chemistry production facility in Finland. The factory operates near the raw material harvest areas. A uniquely short value chain enables an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name EEVIA.

To learn more, please visit  www.eeviahealth.com or follow Eevia Health on LinkedIn @EeviaHealth. 

Läs mer hos Cision
Läs mer om Eevia Health Plc

Prenumeration